Sotera Health Co current report, 11 January 2022

Sotera Health Company — Form 8-K Summary

Business Context and Reporting Period

Sotera Health Company filed a Form 8-K dated January 11, 2022, under Items 2.02, 7.01, and 9.01. The filing concerns updated full-year 2021 revenue guidance, a business update presented at the 40th Annual J.P. Morgan Healthcare Conference, and planned environmental, social, and governance investor engagement.

Financial Metrics and Liquidity

The filing text does not provide a clear numerical value for updated 2021 revenue guidance. It does not report revenue results, profit, cash flow, margins, debt, liquidity, or other financial metrics.

Material Changes Versus Prior Period

The company announced updated guidance for full-year 2021 revenue. The filing does not state the prior guidance, the revised revenue amount, or the expected percentage change versus the prior comparable period.

Guidance, Outlook, Commentary, and Unusual Items

  • The updated 2021 revenue guidance was based on information available as of January 11, 2022.
  • The guidance remained subject to completion of year-end financial closing procedures and the audit by the company’s independent registered public accounting firm.
  • Chairman and CEO Michael B. Petras, Jr. was scheduled to deliver a business update at the J.P. Morgan Healthcare Conference on January 11, 2022.
  • Company representatives planned investor engagement focused on ESG matters on or after January 11, 2022.
  • The referenced information and Exhibits 99.1, 99.2, and 99.3 were furnished, rather than filed, for purposes of Section 18 of the Exchange Act, unless expressly incorporated by reference.

Key Facts for Investors to Verify

  • Review Exhibit 99.1 for the specific revised full-year 2021 revenue guidance and comparison with prior guidance.
  • Confirm the final audited 2021 results after completion of the year-end close and audit.
  • Review Exhibit 99.2 for management’s business update, operating outlook, and any additional financial commentary.
  • Review Exhibit 99.3 for the company’s ESG disclosures and investor engagement topics.